Better drug delivery through the blood-brain barrier

| October 19, 2018

article image
Research on the delivery of therapeutics to the brain could have implications for the treatment of a wide range of diseases, such as Alzheimer’s, ALS, brain cancer and Parkinson’s. Scientists at the University of Rochester Medical Centre (URMC) discovered the approach that should deliver treatments to the brain more effectively than current treatments.

Spotlight

PEPID International

PEPID International products enable doctors, nurses and students to carry advanced medical and drug information resources to the point of care, wherever that may be. Delivered on Smartphones, online and by enterprise information systems, PEPID International products feature internationally comprehensive drug databases, a full spectrum of medical topics, and clinical tools such as a drug interactions generator and thousands of dosing calculators. These resources help caregivers provide more accurate care and avoid adverse events.

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 3, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

The Future of Pharma Beyond Blockbusters

Article | April 3, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 3, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Spotlight

PEPID International

PEPID International products enable doctors, nurses and students to carry advanced medical and drug information resources to the point of care, wherever that may be. Delivered on Smartphones, online and by enterprise information systems, PEPID International products feature internationally comprehensive drug databases, a full spectrum of medical topics, and clinical tools such as a drug interactions generator and thousands of dosing calculators. These resources help caregivers provide more accurate care and avoid adverse events.

Events